(Q30401949)

21 June 2017

title

Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance (English)

1 reference

21 June 2017

0 references

Xavier Kurz

1

1 reference

21 June 2017

François Domergue

2

1 reference

21 June 2017

Jim Slattery

3

1 reference

21 June 2017

Andrej Segec

4

1 reference

21 June 2017

Agnieszka Szmigiel

5

1 reference

21 June 2017

Ana Hidalgo-Simon

6

1 reference

21 June 2017

language of work or name

English

0 references

publication date

16 April 2011

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

26

1 reference

21 June 2017

page(s)

4378-4387

1 reference

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Monitoring HPV vaccination programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Data mining for signals in spontaneous reporting databases: proceed with caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

H1N1 vaccine safety monitoring: beyond background rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

H1N1 vaccine safety: real-time surveillance in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Reassessment of the Association between Guillain-Barré Syndrome and Receipt of Swine Influenza Vaccine in 1976–1977: Results of a Two-State Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

Guillain-Barré syndrome following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.005

10.1016/J.VACCINE.2011.04.005

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference